103 research outputs found
A somatic mutation in the thyrotropin receptor gene in a patient with an autonomous nodule within a multinodular goiter
ABSTRACT Thyrotropin (TSH) is the prime regulator of thyroid cell growth and function and acts through the thyrotropin receptor (TSHR) located on the surface membrane of thyrocytes. Somatic heterozygous mutations that cause TSHR activation in the absence of TSH have been found in toxic adenomas and in hot nodules of multinodular goiters. Clinically and histologically heterogeneous nodules can share common gain-of-function mutations. Mutation prevalence varies greatly and is inversely related to iodine intake of the population. We report a Greek patient presenting with subclinical hyperthyroidism due to a fast-growing autonomous hyperplastic nodule in a long-standing multinodular goiter. Direct DNA sequencing showed that the hot nodule harbored a somatic heterozygous activating TSHR mutation: substitution of glutamine for leucine in the third transmembrane helix. This mutation (L512Q) was recently described in two solitary toxic adenomas. This report expands the spectrum of mutations shared by dissimilar hot nodules, supporting a common mechanism for nonautoimmune thyroid autonomy. The identification of the L512Q substitution demonstrates that gainof-function TSHR mutations are encountered in Greece, although iodine deficiency has been significantly corrected over the last three decades
Congenital Hypogonadotropic Hypogonadism Due to GNRH Receptor Mutations in Three Brothers Reveal Sites Affecting Conformation and Coupling
Congenital hypogonadotropic hypogonadism (CHH) is characterized by low gonadotropins and failure to progress normally through puberty. Mutations in the gene encoding the GnRH receptor (GNRHR1) result in CHH when present as compound heterozygous or homozygous inactivating mutations. This study identifies and characterizes the properties of two novel GNRHR1 mutations in a family in which three brothers display normosmic CHH while their sister was unaffected. Molecular analysis in the proband and the affected brothers revealed two novel non-synonymous missense GNRHR1 mutations, present in a compound heterozygous state, whereas their unaffected parents possessed only one inactivating mutation, demonstrating the autosomal recessive transmission in this kindred and excluding X-linked inheritance equivocally suggested by the initial pedigree analysis. The first mutation at c.845 C>G introduces an Arg substitution for the conserved Pro 282 in transmembrane domain (TMD) 6. The Pro282Arg mutant is unable to bind radiolabeled GnRH analogue. As this conserved residue is important in receptor conformation, it is likely that the mutation perturbs the binding pocket and affects trafficking to the cell surface. The second mutation at c.968 A>G introduces a Cys substitution for Tyr 323 in the functionally crucial N/DPxxY motif in TMD 7. The Tyr323Cys mutant has an increased GnRH binding affinity but reduced receptor expression at the plasma membrane and impaired G protein-coupling. Inositol phosphate accumulation assays demonstrated absent and impaired Gαq/11 signal transduction by Pro282Arg and Tyr323Cys mutants, respectively. Pretreatment with the membrane permeant GnRHR antagonist NBI-42902, which rescues cell surface expression of many GNRHR1 mutants, significantly increased the levels of radioligand binding and intracellular signaling of the Tyr323Cys mutant but not Pro282Arg. Immunocytochemistry confirmed that both mutants are present on the cell membrane albeit at low levels. Together these molecular deficiencies of the two novel GNRHR1 mutations lead to the CHH phenotype when present as a compound heterozygote
The nonthyroidal illness syndrome in the non-critically ill patient
P>Background
The nonthyroidal illness syndrome (NTIS) is a very common clinical
entity among hospitalized patients and has been reported in practically
every severe illness and acute or chronic stressful event. There is a
large body of data associating the presence of NTIS with the severity of
the underlying disease. Most of these studies concern intensive care
unit (ICU) patients, whereas the non-critically ill patients outside the
ICU setting are less well studied.
Design
We provide a review of the existing literature focusing on studies
examining NTIS in non-critically ill patients and attempt to summarize
the pathophysiological pathways underlying the syndrome, its prognostic
role, as well as the current intervention studies mainly from a clinical
standpoint.
Results
The aetiology of the NTIS is multifactorial and varies among different
groups of patients. Experimental and clinical findings suggest that
inflammatory cytokines are implicated in the pathogenesis of the
syndrome, whereas recent evidence re-evaluate the role of deiodinases in
thyroid hormone metabolism not only in the periphery but also in the
hypothalamus and the pituitary and thus in the alterations accompanying
NTIS. Clinical data examining the effectiveness of thyroid hormone
supplementation in NTIS remain controversial.
Conclusions
As long as there is no clear evidence of benefit from thyroid hormone
replacement and until well-designed studies confirm its efficacy,
thyroxine supplementation should not be recommended for the treatment of
NTIS
The failure of physiologic doses of reverse T3 to effect thyroid-pituitary function in man
Reverse T3 (3,3',5'-triiodothyronine, rT3), a major product of the peripheral monodeiodination of thyroxine (T4), was administered to normal male volunteers in doses sufficient to sustain an elevated serum rT3 concentration similar to that frequently observed in patients with nonthyroidal illness. No changes in basal serum T4, T3, TSH and prolactin concentrations, nor in the T3, TSH and prolactin responses to iv TRH were observed during rT3 administration. These findings suggest that physiologic increases in serum rT3 concentration probably do not inhibit T4 to T3 conversion or the anterior pituitary TSH and prolactin responses to thyrotropin-releasing hormone (TRH)
- …